Compare MSA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | BLTE |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.0B |
| IPO Year | 1994 | 2021 |
| Metric | MSA | BLTE |
|---|---|---|
| Price | $179.03 | $162.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $209.14 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 178.9K | 168.4K |
| Earning Date | 07-30-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $1,874,814,000.00 | N/A |
| Revenue This Year | $11.27 | N/A |
| Revenue Next Year | $9.08 | N/A |
| P/E Ratio | $44.79 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $151.11 | $72.65 |
| 52 Week High | $208.92 | $200.00 |
| Indicator | MSA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 51.47 |
| Support Level | $174.70 | $167.28 |
| Resistance Level | $185.54 | $172.02 |
| Average True Range (ATR) | 3.46 | 5.28 |
| MACD | -0.23 | -0.86 |
| Stochastic Oscillator | 33.72 | 39.80 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The company's product offerings include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems, among others. The end markets for its products include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company has organized its business into four geographical operating segments that are aggregated into two reportable segments: Americas and International. The majority of its revenue is generated from the Americas segment, which is comprised of the company's operations in Northern North America and Latin America geographies.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.